Hello, everyone, and how are you today? We are doing just fine, thank you, now that we have deposited the shortest person at the local schoolhouse and attended to the official mascot, who is now happily snoozing in a corner. This means we can attend to the matters at hand — talking to interesting people, digging for saucy items, and keeping up with events. Speaking of which, here are a few items of interest to help jog your own neurons. Hope today is a productive one for you and, as always, feel free to keep in touch with us …

In a shocking reversal, Biogen (BIIB) plans to resurrect an Alzheimer’s drug the company previously said had failed and will ask the Food and Drug Administration for approval, STAT reports. A “new analysis of larger dataset” showed the drug, aducanumab, reduced clinical decline in patients with early Alzheimer’s disease on multiple measures of effectiveness. That directly contradicts a decision in March to halt studies based on the recommendations of an independent monitoring board that was charged with protecting patients in the study.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy